Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “nAMD”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03835884
What this trial is testing

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

Who this might be right for
Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Aerie Pharmaceuticals 18
Large-scale testing (Phase 3)Study completedNCT03954626
What this trial is testing

Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

Who this might be right for
Age-Related Macular DegenerationMacular DegenerationWet Macular Degeneration+3 more
Novartis Pharmaceuticals 14
Testing effectiveness (Phase 2)Temporarily pausedNCT05961007
What this trial is testing

Evaluation of IBI302 Injection in nAMD or DME

Who this might be right for
Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Innovent Biologics (Suzhou) Co. Ltd. 234
Post-approval studies (Phase 4)Study completedNCT01988662
What this trial is testing

UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)

Who this might be right for
Neovacular Age-related Macular Degeneration
Novartis Pharmaceuticals 205
Large-scale testing (Phase 3)WithdrawnNCT04697953
What this trial is testing

Efficacy and Safety of Brolucizumab 6mg in a Treat and Extend Regimen in Patients With Neovascular Age-Related Macular Degeneration (nAMD) With Prior Anti-VEGF Exposure (PEREGRINE)

Who this might be right for
Age-related Macular Degeneration (AMD)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT04832724
What this trial is testing

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular DegenerationWet Macular DegenerationWet Age-related Macular Degeneration
AbbVie 60
Not applicableNot Yet RecruitingNCT07581782
What this trial is testing

Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age-related Macular Degeneration(nAMD)
Sun Yat-sen University 50
Not applicableStudy completedNCT06890026
What this trial is testing

Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)Treatment-naïve
Rigshospitalet, Denmark 742
Not applicableLooking for participantsNCT07640997
What this trial is testing

Real-world Study of Aflibercept 8 mg in nAMD

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
Peking University People's Hospital 300
Large-scale testing (Phase 3)Ended earlyNCT03710564
What this trial is testing

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

Who this might be right for
Age-Related Macular Degeneration
Novartis Pharmaceuticals 535
Large-scale testing (Phase 3)Active Not RecruitingNCT06856577
What this trial is testing

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc. 311
Large-scale testing (Phase 3)Looking for participantsNCT07317934
What this trial is testing

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Innostellar Biotherapeutics Co.,Ltd 388
Early research (Phase 1)Study completedNCT04989699
What this trial is testing

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. 21
Large-scale testing (Phase 3)Active Not RecruitingNCT06491914
What this trial is testing

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Who this might be right for
Neovascular Age-Related Macular DegenerationDiabetic Macular Edema
Regeneron Pharmaceuticals 1,126
Early research (Phase 1)Not Yet RecruitingNCT07764965
What this trial is testing

Evaluation of PAN-90806 Eye Drops in Healthy Subjects

Who this might be right for
Wet Age Related Macular DegenerationNeovascular (Wet) Age-Related Macular Degeneration
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. 20
Not applicableEnded earlyNCT05266495
What this trial is testing

Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 3
Testing effectiveness (Phase 2)UnknownNCT06487039
What this trial is testing

Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration

Who this might be right for
Neovascular Age-related Macular Degeneration (nAMD)
EyebioKorea, Inc. 50
Not applicableUnknownNCT03893474
What this trial is testing

Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners

Who this might be right for
AMD
Moorfields Eye Hospital NHS Foundation Trust 742
Post-approval studies (Phase 4)Study completedNCT06591598
What this trial is testing

Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

Who this might be right for
Diabetic Macular EdemaNeovascular Age-related Macular Degeneration
Bayer 51
Early research (Phase 1)Study completedNCT05345769
What this trial is testing

Safety and Efficacy of AM712 in Patients with NAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
AffaMed Therapeutics Limited 21
Next Page